A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies (JAVELIN Medley)

This is a Phase 1b/2 dose-optimization study to evaluate safety, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of avelumab (MSB0010718C) in combination with other cancer immunotherapies in patients with locally advanced or metastatic solid tumors. The primary purpose is to assess the safety and early signs of efficacy of various avelumab combinations with other cancer immunotherapies, optimizing dosing regimens as appropriate, in a limited series of indications.

本研究为1b/2期剂量优化临床试验，旨在评估阿维单抗（avelumab，MSB0010718C）联合其他癌症免疫疗法，用于局部晚期或转移性实体瘤患者的安全性、药代动力学、药效动力学及初步抗肿瘤活性。本研究的主要目的为在有限的适应证范围内，评估阿维单抗联合多种其他癌症免疫疗法的安全性与早期疗效迹象，并酌情优化给药方案。